Monday, March 21, 2011
Polaris Group, of San Diego, enrolled the first patient in a Phase II trial of ADI-PEG 20 (pegylated arginine deiminase), its enzyme-based treatment for malignant mesothelioma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.